Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs [3] - The company has proprietary platforms for cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADCs, generating a pipeline of product candidates [3] - Current pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of HER2 [3] Recent Developments - On February 3, 2025, Mersana granted an inducement award consisting of a restricted stock unit (RSU) award to acquire 20,610 shares of common stock to a new employee [1] - The RSU award will vest in equal annual installments over four years starting from February 15, 2025, contingent on the employee's continued service [2] - The award is in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to Mersana's 2022 Inducement Stock Incentive Plan [1][2]